American Financial Group, Inc. (AFG) Co-CEO & Co-President Carl Lindner, Sold $20,541,690 in Stock; Biotime (BTX)’s Sentiment Is 1.15

September 24, 2018 - By Clara Lewis

BioTime, Inc. (NYSEAMERICAN:BTX) Logo

Sentiment for Biotime Inc (BTX)

Biotime Inc (BTX) investors sentiment decreased to 1.15 in Q2 2018. It’s down -0.02, from 1.17 in 2018Q1. The ratio dived, as 38 investment professionals opened new and increased stock positions, while 33 reduced and sold holdings in Biotime Inc. The investment professionals in our database now hold: 55.26 million shares, down from 56.08 million shares in 2018Q1. Also, the number of investment professionals holding Biotime Inc in top ten stock positions was flat from 2 to 2 for the same number . Sold All: 14 Reduced: 19 Increased: 26 New Position: 12.

The American Financial Group Inc’s Co-CEO & Co-President, Carl Lindner, the insider unloaded – 181,000 American Financial Group Inc’s shares, based on the market price per share of $113.5 for every share. The mentioned shares now has a value of exactly $20,541,690 USD. This transaction was pretty big one, so clearly it won’t go unseen. Now, Carl Lindner owns 7.77 million shares or about 8.72% of American Financial Group Inc’s total market capitalization.

Since May 7, 2018, it had 0 insider buys, and 5 insider sales for $34.45 million activity. On Wednesday, August 15 the insider LINDNER CARL H III sold $13.33 million. On Friday, June 1 the insider JACOBS TERRY S sold $95,394. 40,000 shares valued at $4.42 million were sold by LINDNER S CRAIG on Monday, May 7.

Investors sentiment increased to 1.23 in Q2 2018. Its up 0.13, from 1.1 in 2018Q1. It is positive, as 26 investors sold American Financial Group, Inc. shares while 98 reduced holdings. 37 funds opened positions while 115 raised stakes. 52.79 million shares or 0.60% more from 52.47 million shares in 2018Q1 were reported. Alphamark Advsrs Limited Liability Com accumulated 0.01% or 220 shares. Toronto Dominion Bank has invested 0% of its portfolio in American Financial Group, Inc. (NYSE:AFG). Mason Street Advisors Ltd Llc holds 0.09% of its portfolio in American Financial Group, Inc. (NYSE:AFG) for 35,578 shares. Massachusetts Fincl Service Ma invested in 0% or 20,862 shares. Verity And Verity Limited Liability invested in 0.15% or 5,135 shares. Regions Financial has 0% invested in American Financial Group, Inc. (NYSE:AFG) for 300 shares. James Investment Rech holds 236,896 shares or 0.97% of its portfolio. Connor Clark And Lunn Mgmt has 3,500 shares for 0% of their portfolio. Bancorporation Of Montreal Can reported 0% stake. Citigroup Inc has 0.01% invested in American Financial Group, Inc. (NYSE:AFG). Utd Svcs Automobile Association holds 0.05% in American Financial Group, Inc. (NYSE:AFG) or 135,381 shares. Sumitomo Mitsui Asset reported 0.01% of its portfolio in American Financial Group, Inc. (NYSE:AFG). Utah Retirement stated it has 13,303 shares. Schwab Charles Mgmt owns 268,434 shares for 0.02% of their portfolio. Ftb Advsr reported 0% in American Financial Group, Inc. (NYSE:AFG).

The stock decreased 1.33% or $1.51 during the last trading session, reaching $112. About 262,018 shares traded. American Financial Group, Inc. (NYSE:AFG) has risen 13.28% since September 25, 2017 and is uptrending. It has underperformed by 2.34% the S&P500. Some Historical AFG News: 02/05/2018 – American Fincl Group 1Q Net $145M; 04/05/2018 – Bill Gates: The American financial aid system is failing students; 02/05/2018 – American Fincl Group 1Q EPS $1.60; 13/03/2018 – American Financial Network, Inc. (AFN) Partners with Valuelnsured to Offer Its Customers Down Payment Protection with AFN Protection+; 22/03/2018 – AFG – AF GRUPPEN TO BUILD TRAIN MAINTENANCE FACILITIES FOR BANE; 01/05/2018 – Detailed Research: Economic Perspectives on NeoGenomics, Illinois Tool Works, Carriage Services, Gorman-Rupp, Fiesta Restaurant; 05/04/2018 – American Financial Volume Jumps More Than Six Times Average; 02/05/2018 – AFG – AF GRUPPEN TO BUILD 56 APARTMENTS AT LØRENSKOG; 28/03/2018 – AFG – AF GRUPPEN BUYS DEVELOPMENT RIGHTS IN CENTRAL GOTHENBURG; 20/03/2018 – North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

American Financial Group, Inc., through its subsidiaries, provides property and casualty insurance products in the United States. The company has market cap of $9.98 billion. It operates through four divisions: Property and Casualty Insurance, Annuity, Run-Off Long-Term Care and Life, and Other. It has a 19.02 P/E ratio. The firm offers property and transportation insurance products, such as physical damage and liability coverage for buses, trucks and recreational vehicles, inland and ocean marine, agricultural-related products, and other property coverages; specialty casualty insurance, including primarily excess and surplus, general liability, executive liability, professional liability, umbrella and excess liability, and specialty coverage in targeted markets and customized programs for small to mid-sized businesses; and specialty financial insurance products comprising risk management insurance programs for leasing and financing institutions, surety and fidelity products, and trade credit insurance.

Analysts await American Financial Group, Inc. (NYSE:AFG) to report earnings on October, 30. They expect $1.79 earnings per share, up 68.87% or $0.73 from last year’s $1.06 per share. AFG’s profit will be $159.47 million for 15.64 P/E if the $1.79 EPS becomes a reality. After $2.04 actual earnings per share reported by American Financial Group, Inc. for the previous quarter, Wall Street now forecasts -12.25% negative EPS growth.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $309.58 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on November, 8. They expect $-0.06 earnings per share, down 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.06 actual earnings per share reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Since January 1, 0001, it had 1 buying transaction, and 0 sales for $3,769 activity.

The stock decreased 7.22% or $0.19 during the last trading session, reaching $2.44. About 528,342 shares traded. BioTime, Inc. (BTX) has declined 22.65% since September 24, 2017 and is downtrending. It has underperformed by 38.27% the S&P500. Some Historical BTX News: 01/05/2018 – BioTime Presents Updated OpRegen(R) Clinical Trial Data at ARVO; 02/05/2018 – Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Associat; 24/05/2018 – BioTime at Non-Deal Roadshow Hosted By Chardan Today; 17/05/2018 – BioTime Non-Deal Roadshow Scheduled By Chardan for May. 24; 25/04/2018 – BioTime Non-Deal Roadshow Scheduled By Chardan for May. 2; 27/03/2018 – BioTime: IVT Holdings Acquired Ascendance Biotechnology Inc; 07/03/2018 BIOTIME ANNOUNCES DSMB APPROVAL TO PROCEED TO COHORT 4 OF THE OPREGEN® CLINICAL TRIAL; 24/05/2018 – BIOTIME INC – EXPANSION OF ONGOING PHASE l/llA CLINICAL TRIAL FOR OPREGEN, WITH ADDITION OF TWO NEW U.S. SITES; 10/05/2018 – BioTime 1Q Loss $63.5M; 10/04/2018 – BioTime at Non-Deal Roadshow Hosted By LifeSci Advisors Today

Broadwood Capital Inc holds 7.09% of its portfolio in BioTime, Inc. for 29.97 million shares. Dafna Capital Management Llc owns 181,600 shares or 0.18% of their US portfolio. Moreover, Prescott General Partners Llc has 0.14% invested in the company for 1.85 million shares. The New York-based Raffles Associates Lp has invested 0.08% in the stock. Berson & Corrado Investment Advisors Llc, a New York-based fund reported 39,275 shares.

American Financial Group, Inc. (NYSE:AFG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts